NuCana PLC (NCNA) Quote

NCNA new 52 week low

NCNA new 52 week low

NCNA...............................................................................https://stockcharts.com/h-sc/ui?s=NCNA&p=W&b=5&g=0&id=p86431144783

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States

$7.36 plus + 150%

Wowser what a wash bot

NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

Source: GlobeNewswire Inc.

NuCana plc (NASDAQ: NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress on NUC-7738 in combination with pembrolizumab for patients with metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor therapy.
In this cohort of 12 patients, most of whom had received at least two prior lines of PD-1 inhibitor therapy, nine (75%) achieved disease control, including two patients who achieved Partial Responses. One of these patients, who had received two prior lines of PD-1 inhibitor-based therapy and had progressed on their latest treatment of ipilimumab plus nivolumab within two months, achieved a 55% reduction in tumor volume. Seven of the 12 patients had a progression free survival time of greater than five months, which is highly atypical in this patient population. In addition to achieving these encouraging efficacy signals, the combination of NUC-7738 and pembrolizumab had a favorable safety profile.

NUC-7738’s ability to sensitize PD-1 resistant tumors to rechallenge with PD-1 inhibitors is believed to be due to its ability to target multiple aspects of the tumor microenvironment (TME) via the disruption of RNA polyadenylation and subsequent changes to gene expression in cancer cells. In support of this hypothesis, data presented from tumor biopsies obtained before and after NUC-7738 based treatment demonstrated increases in genes related to antigen presentation and T-cell activation.

Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer said: “We are very excited to share these data on NUC-7738 in combination with pembrolizumab in PD-1 inhibitor refractory and resistant patients with melanoma. Outcomes in this patient population are very poor, with median progression free survival of 2-3 months with the current standard of care, so we are very encouraged that the majority of patients who received this combination achieved a progression free survival of more than five months.”

Mr. Griffith continued: “The translational data that has been generated in this study and in previous non-clinical studies give us confidence that the effects we are seeing are a result of NUC-7738 making previously resistant tumors sensitive to rechallenge with PD-1 inhibitors by targeting multiple aspects of the tumor microenvironment. Our data on NUC-7738 obtained in other tumor types indicate that this phenomenon is not restricted to melanoma and that NUC-7738 may have the ability to sensitize other PD-1 inhibitor resistant tumor types. We look forward to sharing our development plans for NUC-7738 in the near future.”

About NuCana

NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, they have significant shortcomings that limit their efficacy and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome the key limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s pipeline includes NUC-3373 and NUC-7738. NUC-3373 is a new chemical entity derived from the nucleoside analog 5-fluorouracil, a widely used chemotherapy agent. NUC-3373 is currently being evaluated in two ongoing clinical studies: a Phase 1b/2 study (NuTide:302) in combination with leucovorin, irinotecan or oxaliplatin, and bevacizumab in patients with metastatic colorectal cancer; and a Phase 1b/2 modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer. NUC-7738 is a novel anti-cancer agent that disrupts RNA polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase 2 part of a Phase 1/2 study (NuTide:701) which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma.

Lol

NCNA under $4

NCNA new 52 week low

NCNA announces 1:25 reverse split.

https://finance.yahoo.com/news/nucana-announces-plan-implement-ads-203000210.html

NCNA has until 5/6/2024 to attain NASDAQ's minimum bid requirement of $1.00.

So though not inevitable, I'd agree that the possibility of an RS is highly likely.

Another possibility is for NCNA to partner with a large pharma company to begin one or more clinical trials with one or more of their patented drugs. If they haven't had any conversations about this up to now, I'd say it's highly unlikely any partnership agreement could be finalized in the ~1 month remaining before they will be subject to delisting by NASDAQ.

Needless to say, I'm very glad I was able to sell all my NCNA shares during the recent runup. And I likely won't be buying any shares up to May 6. If NCNA does decide to do a reverse split to remain quoted on NASDAQ, I will reconsider my stance.

I think a reverse split is inevitable

Still on radar but not buying any yet.

Looking for something closer to $.30 or perhaps slightly lower ($.28-.29)

Not in a rush to buy back. Still a chance they get delisted or perhaps execute a reverse split to raise their bid price above $1. A lot of uncertainty in this ticker as far as I'm concerned. Was happy to sell my shares around $.80. Didn't have that many shares but was a nice profit anyway.

Wow. We might see .20’s

Gap looking filled :) I just wonder who’s buying.

Good trade.

In the .40’s. Looks like a good place to grab a little more. Can’t imagine it going into .30’s

NCNA: Whelp, GLAD I dumped this daily Cancer-Patent-Of-The-Hour routine long ago today!!! (See below where MY shares went, hours ago!!!)

NCNA: Great DD, too!!! Boy, I got SUCKERED!! (But, I'll only cry just a few more hours --- see me, live, below!!)


"Yeah, sure!!! And I myself just got a Patent to kill CANCER too!!! I grow the Cancer cells in a Petri Dish, then toss ARCO-PREMIUM-TOP-TIER-GASOLINE on it, and hit it with my Bic CIGARETTE LIGHTER!!! Works every time!!!"

Just did a patent search for NCNA and found ~17 patents they have received using PHOSPHORAMIDATE derivatives.

One dates back to 2016! -lol

https://patents.justia.com/assignee/nucana-plc

NCNA: CONGRATS, Dude!!! You worked it as a PRO would!!! (I worked it like a FOOL!!! Dumped all awhile back, at a LOSS!! Good thing I did NOT 'toss-the-farm' at it!!) And indeed, just like you too emphasized, any OTHER firm would have HYPED-the-fluck out of any kind of Cancer-related Patent, but this firm did NOTHING.)

CONGRATS again!!!

Was "lucky" and got up early this morning.

I was able to sell all my shares pre-market at around $.81 >

You're right to worry about the "stealth" patent though. Most companies would brag about even having an application in process in the US.

Wonder why they have been so secretive about this patent?

NCNA: Most worrisome here --- via my own stupid, belated hindsight --- was that there was NO Company PR, nor otherwise "NEWS", about their own new PATENT. THAT is really, really, really, WORRISOME!!!!

Getting and staying over $1 is a big deal now.

If NCNA can do that they will not be in danger of delisting from NASDAQ. Otherwise delisting or a reverse split might be on the table. They have until May 6, 2024 to meet NASDAQ minimum bid price listing requirement.

https://ir.nucana.com/news-releases/news-release-details/nucana-announces-listing-transfer-nasdaq-capital-market

Same. I have a starter. Will avg down if it hits where I want.

Like I said, NCNA future all depends on what they can do with the patent.

If they are smart they already had "somethings" lined up before the approval. Now that approval has been achieved may take some time to finalize a deal with someone in big pharma. May go back into the 40's if the wait becomes more than a week or 2. But that is just my own guess.

Keeping on my radar for now.

Yeah. It may not happen. It has traded the float above the .50 area. Hit $1 in PM, so maybe it comes again

Low so far today is $.571 >

$.40's seems a stretch at least for today. But if it gets that low will rebuy shares.

Future for this ticker depends on what they do with their brand new US Patent. Sell it outright or use it as "bait" for a partnership with big Pharma? (imo)

I wouldn’t mind seeing it in the .40’s before running though.

NCNA: This may run now, since the FLUFF "news" baloney is OVER at the scam PR of the day, namely, @GXAI.

Let’s see if .40 gap closes.

Let’s see if they can get over $1 and hold

They got the US Patent. Now what?

Strong patent news but over extended seems like, slow day in the market tho and holding so let’s see

NCNA: I think this puppy is on the TOP of this list for SOME reason ---
https://www.benzinga.com/premarket

NCNA: News about Patent for Cancer treatment.
https://beststocks.com/title-nucana-receives-us-patent-for-phosphora/

NCNA: I inadvertently stumbled-up their PATENT news on BENZINGA. (But I guess that EVERYBODY already knew that; heck, see selfie video of ME below, just last week --- at least I'm humble.)

NCNA: Here's today's (reclusive) NCNA Firm's Patent news item:
https://www.benzinga.com/wiim/24/03/37635513/nucana-shares-are-trading-higher-after-the-company-was-granted-u-s-patent-11925658-for-phosphoramida

"NuCana shares are trading higher after the company was granted U.S. Patent #11925658 for Phosphoramidate Derivatives For Use In The Treatment Of Cancer; Especially In The Treatment Where The Patient Shows Resistance"

NCNA: Unfortunately for ME, that's 1:00 a.m.!!! (I HATE San Diego!! By the Open, I get sloppy 3rd's, 4th's, or 5th's. I need WeBull, plus a stay-awake or 'Dracula-Drug'.)

Wonder where this opens come 4am

NCNA: Cancer + England + Lots of Trials --- well, just may be a monster WINNING formula for Wednesday.

NCNA chart

So…..

NCNA new 52 week low

Move yesterday was probably due to anticipated presentations at a Cancer Therapeutics 2023 conference.

https://finance.yahoo.com/news/nucana-announces-presentations-aacr-nci-120000333.html

Moving on low volume

NCNA new 52 week low

NCNA new 52 week low

I think we see $4 soon enough. By the end of this week or next. IMO. $NCNA